SpringWorks Therapeutics
Yahoo Finance • 2 days ago
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric... Full story
Yahoo Finance • 11 days ago
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN– – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in... Full story
Yahoo Finance • 11 days ago
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN– – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in... Full story
Yahoo Finance • 23 days ago
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conferenc... Full story
Yahoo Finance • last year
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
SpringWorks Therapeutics, Inc. STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that... Full story
Yahoo Finance • last year
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
STAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate i... Full story
Yahoo Finance • last year
SpringWorks Catapults 22% On A 'Watershed Moment' In Cancer Treatment
SWTX stock rocketed Tuesday after U.S. regulators signed off on SpringWorks Therapeutics' new cancer treatment for desmoid tumors, Ogsiveo. Continue reading... Full story
Yahoo Finance • last year
SpringWorks non-cancerous tumor drug to be priced at $29,000 per month in US
SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company said on a conference call on Tuesday.... Full story
Yahoo Finance • last year
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quali... Full story
Yahoo Finance • last year
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
– Confirmed objective response rate of 52% in pediatric patients and 41% in adult patients, as assessed by Blinded Independent Central Review – – Mirdametinib treatment resulted in deep and durable responses and significant improvements i... Full story
Yahoo Finance • last year
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 – – On track to report topline data from the Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN in the fourth quarte... Full story
Yahoo Finance • last year
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
- Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools - STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq... Full story
Yahoo Finance • last year
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer... Full story
Yahoo Finance • 2 years ago
11 Best High Short Interest Stocks To Buy Now
In this piece, we will take a look at the 11 best high short interest stocks to buy now. If you want to skip our introduction to short selling and short interest, then take a look at 5 Best High Short Interest Stocks To Buy Now. Short sel... Full story
Yahoo Finance • 2 years ago
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer,... Full story
Yahoo Finance • 2 years ago
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
STAMFORD, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer,... Full story
Yahoo Finance • 2 years ago
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
SpringWorks Therapeutics, Inc. STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 6... Full story
Yahoo Finance • 2 years ago
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- MapKure, LLC, SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160;... Full story
Yahoo Finance • 2 years ago
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes – – New Drug Application Under Review by the FDA with PDUFA Action Date of August 27, 2023 – STAMFORD, C... Full story
Yahoo Finance • 2 years ago
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer... Full story
